等待开盘 11-12 09:30:00 美东时间
-3.140
-1.58%
BWX Technologies Inc's (NYSE:BWXT) short interest as a percent of float has fal...
今天 00:00
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
11-10 17:17
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
11-10 10:22
BWX Technologies (BWXT) priced a $1.1 billion private offering of 0% convertible senior notes due 2030, up from the previously planned $1.0 billion. The notes will not bear regular interest and will m...
11-06 21:20
今日重点评级关注:瑞银:维持Syndax Pharmaceuticals"买入"评级,目标价从35美元升至38美元;HC Wainwright & Co.:维持Benitec Biopharma"买入"评级,目标价从28美元升至35美元
11-05 10:35
Truist Securities analyst Michael Ciarmoli maintains BWX Technologies (NYSE:BWXT) with a Hold and raises the price target from $173 to $200.
11-04 23:31
BWX Technologies (BWXT) declares $0.25/share quarterly dividend, in line with previous. Forward yield 0.46% Payable Dec. 10; for shareholders of record Nov. 19; ex-div Nov. 19. See BWXT Dividend Score...
11-04 14:47
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据BWXT 2025年第三季度业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** - Q3 2025总营收8.66亿美元,同比增长29% - 剔除收购影响的有机营收增长12% - 政府业务营收同比增长10%(包含AOT收购约3%贡献) - 商业业务营收同比增长122%(有机增长38%),主要受Kinetrix收购、商业核电和医疗同位素业务增长推动 **盈利能力:** - 调整后EBITDA为1.51亿美元,同比增长19% - 调整后每股收益1.00美元,同比增长20% - 政府业务调整后EBITDA利润率19.2% -
11-04 12:14
BWX Technologies (NYSE:BWXT) raises FY2025 Adj EPS guidance from $3.65-$3.75 to $3.75-$3.80 vs $3.74 analyst estimate. Affirms FY2025 sales outlook from $3.100 billion to $3.100 billion vs $3.114 billion estimate.
11-04 05:17